Brett King, MD, PhD
Associate Professor of DermatologyDownloadHi-Res Photo
Cards
Appointments
Dermatology
Primary
Contact Info
Dermatology
1625 Straits Turnpike, Suite 211
Middlebury, CT 06762
United States
About
Titles
Associate Professor of Dermatology
Biography
Dr. Brett King is Associate Professor of Dermatology, specializing in skin diseases recalcitrant to first-line therapies. He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, erosive lichen planus, and other disorders. He sees patients at Yale Dermatology-Middlebury.
Dr. King provides care of patients with all dermatologic conditions, with special interest in:
- atopic dermatitis (eczema)
- alopecia areata
- androgenetic alopecia (male pattern and female pattern hair loss)
- vitiligo
He is experienced with the use of systemic medications including:
- JAK inhibitors, e.g. tofacitinib (Xeljanz®), baricitinib (Olumiant®), upadacitinib (Rinvoq®), ruxolitinib (Jakafi®) and ruxolitinib 1.5% cream (Opzelura®), abrocitinib (Cibinqo®), ritlecitinib (Litfulo®)
- ‘biologics’, e.g. dupilumab (Dupixent®), adalimumab (Humira®), sekucinumab (Cosentyx®), ixekizumab (Taltz®), etc.
- apremilast (Otezla®), retinoids, methotrexate, cyclosporine, azathioprine, mycophenolate mofetil
- phototherapy
Dr. King is an investigator in numerous clinical trials. He lectures nationally and internationally and publishes extensively.
Dr. King received his B.A. at the University of California at Santa Cruz, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency at Yale University School of Medicine.
Appointments
Dermatology
Associate Professor on TermPrimary
Other Departments & Organizations
- Cutaneous Granulomatous Disorders Program
- Dermatology
- Medical Dermatology
- Middlebury Dermatology
- Yale Ventures
Education & Training
- Fellowship
- Yale-New Haven Hospital (2010)
- Residency
- Yale-New Haven Hospital (2009)
- Internship
- Massachusetts General Hospital (2006)
- MD
- Yale University School of Medicine (2005)
- PhD
- Stanford University, Chemistry (2000)
- BA
- University of California at Santa Cruz, Chemistry (1992)
Board Certifications
Dermatology
- Certification Organization
- AB of Dermatology
- Original Certification Date
- 2009
Research
Overview
Medical Research Interests
Alopecia Areata; Dermatitis, Atopic; Eczema; Granuloma Annulare; Sarcoidosis; Scleroderma, Limited; Stevens-Johnson Syndrome; Vitiligo
Research at a Glance
Yale Co-Authors
Frequent collaborators of Brett King's published research.
Publications Timeline
A big-picture view of Brett King's research output by year.
Research Interests
Research topics Brett King is interested in exploring.
William Damsky, MD, PhD
Sa Rang Kim, MD
Brittany Craiglow, MD
Matthew Vesely, MD, PhD
Edward J Miller, MD, PhD
Goran Micevic, MD, PhD
117Publications
3,103Citations
Alopecia Areata
Vitiligo
Dermatitis, Atopic
Sarcoidosis
Granuloma Annulare
Eczema
Publications
2024
Cutaneous sarcoidosis: clinical and pathologic features, molecular pathogenesis, and treatment
Damsky W, King B. Cutaneous sarcoidosis: clinical and pathologic features, molecular pathogenesis, and treatment. Clinics In Dermatology 2024 PMID: 39694198, DOI: 10.1016/j.clindermatol.2024.12.017.Peer-Reviewed Original ResearchConceptsCutaneous manifestations of sarcoidosisManifestation of sarcoidosisMultisystem inflammatory disorderFDA-approved therapiesLevel of evidenceCutaneous involvementCutaneous sarcoidosisCutaneous manifestationsHistopathological findingsInflammatory disordersSarcoidosisLymphatic systemTreatment approachesDisease pathogenesisRecommended evaluationDiseasePrednisoneCorticotropinTherapyPatientsMultisystemLungPathogenesisEfficacité à long terme du baricitinib dans le traitement de la pelade : résultats à 3ans des études BRAVE-AA1 et BRAVE-AA2
Senna M, Mostaghimi A, Ohyama M, Sinclair R, Chiasserini C, Dutronc Y, Somani N, Yu G, Kolodsick J, King B, Hebert V. Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à 3ans des études BRAVE-AA1 et BRAVE-AA2. Annales De Dermatologie Et De Vénéréologie - FMC 2024, 4: a367. DOI: 10.1016/j.fander.2024.09.434.Peer-Reviewed Original ResearchDélai de repousse des sourcils et des cils dans les sous-groupes de patients atteints de pelade sévère répondant au traitement par baricitinib au niveau du cuir chevelu
King B, Shapiro J, Senna M, Ohyama M, Dutronc Y, Lu N, Chiasserini C, Somani N, Piraccini B, Reguiai Z. Délai de repousse des sourcils et des cils dans les sous-groupes de patients atteints de pelade sévère répondant au traitement par baricitinib au niveau du cuir chevelu. Annales De Dermatologie Et De Vénéréologie - FMC 2024, 4: a368. DOI: 10.1016/j.fander.2024.09.435.Peer-Reviewed Original ResearchRésultats de la diminution de la dose chez les patients atteints de pelade sévère et traités par baricitinib : mise à jour jusqu’à la semaine 152 de l’essai BRAVE-AA2
King B, Ohyama M, Shapiro J, Senna M, Dutronc Y, Liu C, Yu G, Chiasserini C, Kolodsick J, Piraccini B, Hebert V. Résultats de la diminution de la dose chez les patients atteints de pelade sévère et traités par baricitinib : mise à jour jusqu’à la semaine 152 de l’essai BRAVE-AA2. Annales De Dermatologie Et De Vénéréologie - FMC 2024, 4: a368-a369. DOI: 10.1016/j.fander.2024.09.436.Peer-Reviewed Original ResearchObtention de réponses significatives sur le cuir chevelu sous baricitinib chez les patients atteints de pelade sévère non répondeurs sur le cuir chevelu mais ayant obtenu une repousse des cils et sourcils au cours de la première année
Mostaghimi A, Augustin M, Harada K, Senna M, Dutronc Y, Yu G, Ball S, Murage M, Kolodsick J, King B, Hebert V. Obtention de réponses significatives sur le cuir chevelu sous baricitinib chez les patients atteints de pelade sévère non répondeurs sur le cuir chevelu mais ayant obtenu une repousse des cils et sourcils au cours de la première année. Annales De Dermatologie Et De Vénéréologie - FMC 2024, 4: a365-a366. DOI: 10.1016/j.fander.2024.09.432.Peer-Reviewed Original ResearchContinued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
Mostaghimi A, Augustin M, Harada K, Senna M, Dutronc Y, Yu G, Ball S, Murage M, Kolodsick J, Brogan Y, King B. Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year. Journal Of The European Academy Of Dermatology And Venereology 2024 PMID: 39569884, DOI: 10.1111/jdv.20334.Peer-Reviewed Original ResearchCharacterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Vleugals R, Mostaghimi A, Sinclair R, Piraccini B, Sontag A, Somani N, Denning K, Srivastava A, King B. Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s466. DOI: 10.25251/skin.8.supp.466.Peer-Reviewed Original ResearchConceptsLipid-lowering medicationsLipid lowering medicationEffects of JAK inhibitorsLDL-CAlopecia areataHDL-CBaricitinib treatmentHDL-C.Lipoprotein cholesterolTotal cholesterolTreatment-emergent adverse eventsJAK inhibitorsInitiation of lipid-lowering medicationsLipid levelsBaricitinib 2 mgDose of baricitinibTreated with baricitinibLow-density lipoprotein cholesterolClass effectHigh-density lipoprotein cholesterolSevere alopecia areataBaricitinib 4 mgPrevalence of hypercholesterolemiaDose changesLipid abnormalitiesPatient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Sinclair R, Mesinkovska N, Mitra D, Wajsbrot D, Law E, Wolk R, King B. Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial. American Journal Of Clinical Dermatology 2024, 1-11. PMID: 39441519, DOI: 10.1007/s40257-024-00899-4.Peer-Reviewed Original ResearchConceptsSeverity of Alopecia ToolScalp hair lossAlopecia areataHair lossEmotional symptomsActivity limitationsSeverity of Alopecia Tool scoreMean changePatient-reported impactBody hair lossRandomized clinical trialsClinician-reported outcomesExploratory endpointsSecondary endpointsRitlecitinibClinical trialsAL scoreHair regrowthWeek 4Priority outcomesPlaceboOutcome instrumentsPatientsConsistent with improvementsDomain scoresOutcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Initially Treated with Baricitinib 4-mg: Week 152 data from BRAVE-AA2
King B, Ohyama M, Senna M, Shapiro J, Dutronc Y, Durand F, Liu C, Yu G, Kolodsick J, Chiasserini C, Somani N, Piraccini B. Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Initially Treated with Baricitinib 4-mg: Week 152 data from BRAVE-AA2. Journal Of The American Academy Of Dermatology 2024 PMID: 39447758, DOI: 10.1016/j.jaad.2024.09.072.Peer-Reviewed Original ResearchConceptsBaricitinib 4 mgDown-titrationTreated patientsAlopecia areataClinical responsePatients maintained responseScalp alopecia areataSevere alopecia areataSustained treatment responseMaintained clinical responseLoss of treatment benefitJanus kinase inhibitorsSevere AASALT scoreTreatment responseClinical factorsEfficacy resultsSustained responseKinase inhibitorsPatientsTreatment benefitResponder statusTreating adultsSub-studyWeeksEfficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, Magnolo N, Piraccini B, Luo X, Wolk R, Woodworth D, Schaefer G, Lejeune A. Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. British Journal Of Dermatology 2024, ljae365. PMID: 39432738, DOI: 10.1093/bjd/ljae365.Peer-Reviewed Original ResearchConceptsSeverity of Alopecia ToolAlopecia areataSafety profilePGI-CSeverity of Alopecia Tool scorePhase 3 clinical studiesDaily loading dosesPhase 2b/3 studyPatient Global ImpressionProportion of patientsScalp hair lossPhase 2b/3Long-term useData cutoffOpen-labelTolerability profileLoading doseClinician-reported severityAdolescent patientsGlobal ImpressionSustained efficacyRitlecitinibPhase 2aPatientsTreatment groups
Academic Achievements & Community Involvement
honor Patient Care Hero
National AwardAmerican Academy of Dermatology (AAD)Details05/04/2022United States
News
News
- June 26, 2023Source: YaleNews
FDA Approves Second Yale-Researched Treatment for Alopecia Areata
- May 17, 2023
Changing the Lives of Patients With Alopecia and Vitiligo
- May 05, 2023
Yale Dermatologists Named Connecticut’s ‘Top Doctors’
- August 18, 2022Source: The New York Times
An Old Medicine Grows New Hair for Pennies a Day, Doctors Say
Get In Touch
Contacts
Email
Appointment Number
Clinic Fax Number
Mailing Address
Dermatology
1625 Straits Turnpike, Suite 211
Middlebury, CT 06762
United States